Recent Updates
Recently added Catalysts
CDNA Positive Sentiment

CareDx Announces Second Quarter 2026 Financial Results

Thursday, July 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CareDx, Inc. reported its financial results for the second quarter of 2026, highlighting a significant revenue increase of 52% compared to the previous year. The company's Testing Services revenue also saw a notable rise of 61%, with approximately 58,000 tests performed, marking a 17% increase in volume. These results reflect strong growth in the company's precision medicine diagnostics business.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue increased by 52% year-over-year.
  • Testing Services revenue rose by 61% year-over-year.
  • Testing Services volume grew by 17%.

Full Press Release Details

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $132 million, an increase of 52% year-over-year Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-o

Frequently Asked Questions

What were CareDx's total revenues for Q2 2026?

CareDx reported total revenues of $132 million for the second quarter of 2026.

How much did Testing Services revenue increase?

Testing Services revenue increased by 61% year-over-year.

What was the Testing Services volume in Q2 2026?

The Testing Services volume was approximately 58,000 in the second quarter of 2026.

What is the year-over-year revenue growth percentage?

The year-over-year revenue growth percentage was 52%.

ShareAdd on Google
Tags: CDNA Viatris Investor Conferences Healthcare CareDx financial results revenue growth testing services
Last updated: Jul 30, 2026

Biotech snapshot

Cash runway
$187M liquidity · $0M/mo burn
Low dilution risk